Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02935595 · ClinicalTrials.gov registry record · Phase 2
Low Dose Intravenous Ketamine in Treatment Resistant Depression Patients
A Phase 2 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT02935595 is a Phase 2 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 9 participants.
The verdict
NCT02935595, a Phase 2 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The primary goal of the project is to study the effect of Ketamine on cortical neurophysiological function in TRD patients. The proposal employs robust and non-invasive neurophysiological techniques TMS and EEG to investigate the cortical excitability and oscillatory activity in patients with treatment resistant depression.
Interventions
- DRUG Ketamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2016-10-14 |
| Est. Completion | 2017-08-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02935595
The ClinicalTrials.gov registry entry for NCT02935595 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ketamine is the first listed.
NCT02935595 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02935595 about?
NCT02935595 is a clinical study titled "Low Dose Intravenous Ketamine in Treatment Resistant Depression Patients". The primary goal of the project is to study the effect of Ketamine on cortical neurophysiological function in TRD patients. The proposal employs robust and non-invasive neurophysiological techniques TMS and EEG to investigate the cortical excitability and oscillatory activity in patients with treatm...
What is the current status of trial NCT02935595?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2016-10-14. Estimated completion is 2017-08-16.
What interventions are being tested in trial NCT02935595?
The interventions under investigation include: Ketamine (DRUG).
Who is sponsoring clinical trial NCT02935595?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.